Related Experiment Video
Updated: Sep 27, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
Philippe Moreau1,2, Cyrille Touzeau1,2
1Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France; and.
Bispecific antibodies are monoclonal antibodies targeting both a surface molecule on the malignant plasma cells and CD3 on T cells, leading to tumor cell death by activated T cells. Bispecific antibodies targeting B-cell maturation antigen, GPRC5D or FcRH5, demonstrated promising efficacy with favorable safety profile in patients with triple-class refractory multiple myeloma. This novel immunotherapeutic modality will likely change the treatment paradigm in the coming years.
Bispecific antibodies are monoclonal antibodies targeting both a surface molecule on the malignant plasma cells and CD3 on T cells, leading to tumor cell death by activated T cells. Bispecific antibodies targeting B-cell maturation antigen, GPRC5D or FcRH5, demonstrated promising efficacy with favorable safety profile in patients with triple-class refractory multiple myeloma. This novel immunotherapeutic modality will likely change the treatment paradigm in the coming years.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
